Acticor Biotech (XPAR:ALACT) ROCE % : -279.68% (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Acticor Biotech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Acticor Biotech's annualized ROCE % for the quarter that ended in Jun. 2023 was -279.68%.

Acticor Biotech ROCE % Historical Data

The historical data trend for Acticor Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acticor Biotech ROCE % Chart

Acticor Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-246.54

-58.88

-102.86

-128.78

-150.62

Acticor Biotech Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
ROCE %	Get a 7-Day Free Trial				-165.82	-106.78	-140.64	-239.54	-279.68

Acticor Biotech ROCE % Calculation

Acticor Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-15.112	/	( ( (17.881 - 4.057)	+	(12.943 - 6.701) )	/ 2 )
	=	-15.112	/	( (13.824	+	6.242)	/ 2 )
	=	-15.112	/	10.033
	=	-150.62 %

Acticor Biotech's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2023 )		(Q: Dec. 2022 )		(Q: Jun. 2023 )
	=	-16.694	/	( ( (12.943 - 6.701)	+	(14.302 - 8.606) )	/ 2 )
	=	-16.694	/	( ( 6.242	+	5.696 )	/ 2 )
	=	-16.694	/	5.969
	=	-279.68 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2023) EBIT data.

Acticor Biotech (XPAR:ALACT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Acticor Biotech ROCE % Related Terms

Thank you for viewing the detailed overview of Acticor Biotech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Acticor Biotech (XPAR:ALACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acticor Biotech SA (XPAR:ALACT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

7V7:Germany

Address

82 Avenue du Maine, Wojo Building, Paris, FRA, 75014

Website

https://www.acticor-biotech.com

Acticor Biotech SA is a clinical stage biopharmaceutical company. It is developing a treatment for cardiovascular emergencies, with a primary focus on Acute Ischemic Stroke.

Acticor Biotech (XPAR:ALACT) Headlines

No Headlines